Overview

• U.S. body contouring provider's Q1 revenue was flat yr/yr, case volume up 0.2%

• Adjusted EPS for Q1 improved yr/yr, adjusted EBITDA declined

• Company reaffirmed full-year 2026 revenue and adjusted EBITDA guidance

Outlook

• Company reaffirms 2026 revenue guidance of $151 mln to $157 mln

• Company maintains 2026 adjusted EBITDA outlook of $15 mln to $17 mln

• AirSculpt expects seasonally strong Q2 driven by enhanced sales and marketing initiatives

Result Drivers

• SAME-CENTER SALES - Co said Q1 revenue was stabilized by positive same-center sales growth

• SALES & MARKETING INITIATIVES - Co attributed building same-center sales to enhanced and elevated sales and marketing initiatives

Company press release: ID:nGNX61zK92

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Revenue	Slight Beat*	$39.40 mln	$39.25 mln (2 Analysts)
Q1 Adjusted EPS	Beat	-$0.01	-$0.02 (2 Analysts)
Q1 Net Income		-$2.40 mln
Q1 Adjusted EBITDA	Miss	$3.30 mln	$3.35 mln (2 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the healthcare facilities & services peer group is "buy."

• Wall Street's median 12-month price target for AirSculpt Technologies Inc is $3.00, about 13.3% below its May 7 closing price of $3.46

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.